Harvard tests AI as Cancer-Detecting partner for doctors
NCT ID NCT07203885
Summary
This study tested whether artificial intelligence (AI) could help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately. Doctors reviewed bone marrow samples with and without AI assistance to see if the technology improved their diagnostic performance. The goal was to understand if AI could serve as a helpful tool in the challenging process of identifying this specific cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE PROMYELOCYTIC LEUKEMIA (APL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harvard Medical School
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.